Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Opthea Spon American Depositary Receipts Representing 8 Ord Shs OPT

Alternate Symbol(s):  CKDXF

Healthcare Biotechnology
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two... see more

Recent & Breaking News (NDAQ:OPT)

Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 7 days ago

Opthea's Wet AMD Program to be Featured at FLORetina 2024

GlobeNewswire November 26, 2024

Opthea to Participate in Citi 2024 Global Healthcare Conference

GlobeNewswire November 25, 2024

Opthea Appoints Kathy Connell to Board of Directors

GlobeNewswire November 15, 2024

Opthea's Wet AMD Program Featured at Ophthalmology Events

GlobeNewswire November 12, 2024

Opthea to Participate in November Investor Conferences

GlobeNewswire November 4, 2024

Opthea Files Notice of Annual General Meeting

GlobeNewswire October 16, 2024

Opthea Wet AMD Program to be Presented at Innovate Retina

GlobeNewswire October 10, 2024

Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

GlobeNewswire October 8, 2024

Opthea to Participate in the UBS Virtual Ophthalmology Day 2024

GlobeNewswire September 30, 2024

Opthea Joins the S&P/ASX 300 Index

GlobeNewswire September 23, 2024

Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept

GlobeNewswire September 18, 2024

Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight

GlobeNewswire September 10, 2024

Opthea Announces Executive Leadership Changes and Senior Hires

GlobeNewswire September 5, 2024

Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference

GlobeNewswire September 3, 2024

Opthea Reports Full-Year Financial Results and Business Updates

GlobeNewswire August 30, 2024

Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024

GlobeNewswire August 8, 2024

Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

GlobeNewswire July 17, 2024

Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer

GlobeNewswire July 14, 2024

Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD

GlobeNewswire July 9, 2024